PM+: Rare cancers a major EU public health problem
A new system of European reference networks would improve cancer patient treatment, argues Paolo G. Casali.
On world cancer day (4 February), we would like to highlight the specific battles that rare cancer patients face and underline the need for dedicated European reference networks for rare cancers.
Twenty per cent of all cancer cases diagnosed in Europe annually are rare, so taken together, they are not so rare. Every year, over four million Europeans are diagnosed with a rare cancer.
"Twenty per cent of all cancer cases diagnosed in Europe annually are rare, so taken together, they are not so rare"
Rare cancers pose a unique set of challenges, issues such as late or incorrect diagnosis, difficulties in finding clinical expertise and accessing appropriate treatments, and difficulties in carrying out clinical studies due to the small number of patients.
There are also issues regarding the funding of research for innovative therapies due to small markets, uncertainty in clinical decision-making, scarcity of registries, guidelines and tissue banks
Rare cancers bring great distress to patients and their caregivers. Due to the particular difficulties they pose, rare cancer patients face an additional burden of uncertainty. Access to expert opinion is crucial and may entail travelling long distances, often across national borders.
The EU has decided to provide support to rare diseases across the EU and to set up European reference networks (ERNs) focusing specifically on improving care and quality of life of patients.
The cross-border healthcare directive gave the European commission the mandate to support member states in developing ERNs between healthcare providers and centres of expertise.
By connecting highly qualified health professionals from across the EU, the aim of ERNs is to advance highly specialised healthcare and provide a concentration of knowledge and resources, especially in areas where resources are scarce, such as rare cancers.
The burden of rare cancers on society has not yet been adequately estimated but is recognised as a major public health problem.
"Let's not miss this opportunity to offer hope, support and novel solutions to rare cancer patients"
Rare cancers include all childhood cancers, most hematologic malignancies and several types of adult solid cancers. Over 186 rare cancers have been identified and grouped into more than ten 'families'.
One way to improve diagnosis, treatment and quality of care for rare cancer patients is to concentrate treatment in specialised centres. Once identified, they can be linked through reference networks.
ERNs dedicated to rare cancers allowing a centralised review system, would contribute to decrease the number of pathologic misdiagnoses and improve quality of treatment.
ERNs would also allow progress on registries, clinical trials and sharing of knowledge about rare cancers between doctors (oncologists and pathologists) and patients alike.
Rare cancers Europe (a multi-stakeholder initiative including doctors, patients, academic institutions, oncology societies, and the industry) is therefore calling for the creation of specific ERNs for each of the identified families of rare cancers.
Let's not miss this opportunity to offer hope, support and novel solutions to rare cancer patients. Join forces with us to call for the prompt creation of European reference networks dedicated to rare cancers.
This content is published by the Parliament Magazine on behalf of our partners.
The European Union’s new regulation on novel food has formally come into force.
MEPs are set to approve an extension of EU export controls on cyber-surveillance tools.
The European Economic Social Committee has urged the EU and member states to adopt a European-level cybersecurity model.
Heinz Becker explains why he's backing plans to make Parkinson’s disease a priority health challenge for EU policymakers.
Commission's plans for harmonising veterinary medicine authorisation need review, argues IFAH-Europe's ...
Cancer is a global scourge requiring a global solution, say ESMO's Fortunato Ciardiello and Alexandru Eniu.